1. Taiwan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Sofiva Genomics Co., Ltd.

Sofiva Genomics Co., Ltd.

TTPEX:6615
33.00
TWD
+0.10
(+0.30%)
0.67EPS
56.30P/E
782.76MMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.48
38.15
34.15
23.56
22.69
21.88
24.06
23.03
23.89
23.21
21.85
21.1
17.86
17.16
Basic EPS, GAAP
-1.39
2.9
1.61
2.65
2.41
2.26
2.96
1.63
2.68
2
0.54
0.86
-0.43
0.64
Free Cash Flow per Basic Share
-1.78
0.55
-0.32
2.24
1.6
1.25
3.69
2.12
3.17
-0.87
-0.04
0.49
0.33
0.99
Dividend per Share
- -
- -
- -
0.24
2
2.01
2
2.6
1.4
2
1
0.2
0.3
- -
Book Value per Share
2.63
5.64
10.41
15.51
15.95
23.36
24.24
25.98
29.22
29.35
28.94
29.83
29.09
30.02
Tangible Book Value per Share
2.58
5.49
10.27
15.42
15.89
23.32
24.04
25.8
28.93
29.04
28.61
29.45
28.85
29.71
Basic Weighted Avg Shares
16
8
10
16
19
21
21
21
21
21
21
21
22
22
Sales/Revenue/Turnover
154
295
344
384
424
459
509
489
508
496
467
453
386
379
Operating Margin (%)
-16.43
7.73
5.56
13.53
12.39
11.67
13.2
4.21
6.9
0.67
-3.4
-0.74
-8.74
-4.91
Depreciation Expense
7
10
15
18
18
23
41
48
42
43
41
42
42
41
Net Income, GAAP
-23
22
16
43
45
47
63
35
57
43
12
18
-9
14
Effective Tax Rate (%)
- -
2.14
13.53
17.5
17.51
9.37
17.2
8.24
10.87
8.86
- -
19
- -
20.38
Profit Margin (%)
-14.66
7.6
4.71
11.25
10.61
10.31
12.3
7.08
11.21
8.63
2.47
4.07
-2.43
3.75
Working Capital
5
29
99
218
207
330
251
234
250
208
181
189
165
176
LT Debt
- -
- -
8
- -
- -
- -
94
86
71
61
49
37
22
15
Total Equity
37
78
145
290
299
495
515
553
624
627
618
644
628
648
Return on Invested Capital (%)
- -
30.98
11.13
16.84
13.71
11.65
9.58
2.97
4.56
0.49
- -
-0.4
- -
-2.17
Return on Capital (%)
- -
31
11.48
17.52
14.59
11.42
11.33
5.75
8.56
6.18
- -
2.7
- -
2.09
Return on Common Equity (%)
- -
39
14.53
19.89
15.29
11.94
12.43
6.49
9.68
6.84
1.85
2.92
-1.47
2.22

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
14
14
23
LT Borrowings
- -
- -
- -
LT Finance Leases
22
19
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
651
736
783

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
236
230
245
Cash, Cash Equivalents & STI
125
121
132
Accounts Receivable, Net
51
54
52
Inventories
35
32
26
Total Current Liabilities
71
66
69
Payables & Accruals
- -
- -
- -
ST Debt
14
14
23
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
19.39%
2.74%
-2.48%
Free Cash Flow
-265.03%
-307.02%
-31.85%
Net Income, GAAP
3.9%
-24.86%
-150.79%
Sales/Revenue/Turnover
1.5%
-4.43%
-14.91%
Total Cash Common Dividend
- -
-16.17%
51.64%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
121
123
106
103
453
2025
96
101
93
96
386
2026
93
97
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
0.45
0.08
-0.25
0.86
2025
-0.15
-0.02
-0.05
-0.21
-0.43
2026
0.67
0.25
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.2
2025
- -
- -
- -
- -
0.3
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chia-Cheng Hung
Full Time Employees
15
Sector
Health services
Industry
Medical/Nursing services
Address
No. 27, Baoqing Road Taipei TPE Taiwan 10043
IPO Date
Jan 5, 2017
Website
sofivagenomics.com.tw
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Sofiva Genomics Co.,Ltd. delivers comprehensive genetic testing services, operating across Taiwan and internationally. The company features six core product lines: reproductive medicine, prenatal and pre-pregnancy care, newborn screening, oncology, precision medication, and rare diseases. For expectant parents, offerings include non-invasive prenatal screening (NIPS) for chromosomal anomalies, microdeletions, and specific single-gene mutations; advanced array analysis; and karyotyping. Additionally, the company provides preimplantation genetic testing for aneuploidy (PGT-A) to support assisted reproduction. In the cancer diagnostics sector, Sofiva Genomics focuses on early detection through novel ctDNA genetic testing technology and offers homologous recombination deficiency (HRD) testing for ovarian cancer. Services also encompass general cancer screening, real-time tumor monitoring, and hereditary cancer risk assessments, including specific tests for breast, colon, ovarian, and endometrial cancers, alongside human papillomavirus (HPV) screening. The firm has integrated its testing items for various solid tumors and hematologic cancers into Taiwan's National Health Insurance next-generation sequencing (NGS) reimbursement system. The company extends its expertise to newborn genetic screenings, featuring broad baby scans, assessments for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome, congenital cytomegalovirus infections, and atopic dermatitis predispositions. Beyond these, Sofiva Genomics offers genetic testing for rare conditions, insights for precision medication, and newly targets the Alzheimer's genetic screening market, specifically APOE testing, as part of its strategic expansion into preventive health. Supplemental services involve biochemical and chromosome analyses, alongside essential advisory and support provisions. Sofiva Genomics caters to future parents, individuals and families navigating genetic disorders, and a growing network of medical institutions. Established in 2012, the company maintains its headquarters in Taipei, Taiwan, and is actively expanding its presence into international markets like Thailand and Japan.